Pfizer Inc (PFE)

He likes it. It is a way to play the vaccines. He has had MRNA-Q in the portfolio for a while. The growth of vaccines will be with us for some time. He feels the growth is there. He prefers to play the group through an ETF like XBI-T. You are going to see more money spent in vaccinations and they will be with us for a long, long time.

They're not in warp speed now, given the problems in vaccine distribution in various states. Pfizer's problem is that it isn't innovative like Eli Lilly or Bristol-Myers.

An area that's started to act better recently. Well managed. But doesn't understand what the catalysts are. Doesn't find it compelling. Consider the picks and shovels instead, like Agilent or Danaher, who benefit from growth in everyone's pipeline.

A core name, but it's hard for big pharma names like this to find a product to drive growth. He prefers biotechs which offer better growth, even ETFs like IBB.

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.